Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone is a long-acting synthetic corticosteroid with negligible mineralocorticoid activity. It is fluorinated at position 9 and is approximately 25 times more potent than hydrocortisone. Dexamethasone acts by binding to the glucocorticoid receptor inside cells, leading to changes in gene expression that suppress pro-inflammatory mediators (such as eosinophils, mast cells, macrophages, interleukins) and upregulate anti-inflammatory mediators. This results in reduced synthesis of prostaglandins and leukotrienes and overall immunosuppression. Dexamethasone is used to treat a wide range of conditions including inflammatory disorders (such as arthritis and skin diseases), allergic reactions, certain cancers (like multiple myeloma), adrenal insufficiency, severe allergies or asthma attacks, ulcerative colitis flare-ups, nervous system disorders like multiple sclerosis exacerbations or myasthenia gravis crises. It can be administered orally or by injection[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone.